key: cord-1029446-8hb9uqfh
authors: Beaudoin-Bussières, Guillaume; Arduini, Ariana; Bourassa, Catherine; Medjahed, Halima; Gendron-Lepage, Gabrielle; Richard, Jonathan; Pan, Qinghua; Wang, Zhen; Liang, Chen; Finzi, Andrés
title: SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicity
date: 2022-03-30
journal: bioRxiv
DOI: 10.1101/2022.03.30.486403
sha: ce4b188f938a62e881024418b9aa4e8130f158e4
doc_id: 1029446
cord_uid: 8hb9uqfh

SARS-CoV-2 Spike glycoprotein is the major target of host neutralizing antibodies and the most changing viral protein in the continuously emerging SARS-CoV-2 variants as a result of frequent viral evasion from host antibody responses. In addition, SARS-CoV-2 encodes multiple accessory proteins that modulate host antiviral immunity by different mechanisms. Among all SARS-CoV-2 accessory proteins, ORF8 is rapidly evolving and a deletion in this protein has been linked to milder disease. Here, we studied the effect of ORF8 on peripheral blood mononuclear cells (PBMC). Specifically, we found that ORF8 can bind monocytes as well as NK cells. Strikingly, ORF8 binds CD16a (FcγRIIIA) with nanomolar affinity and decreases the overall level of CD16 at the surface of monocytes and, to a lesser extent, NK cells. Strikingly, this decrease significantly reduces the capacity of PBMCs and particularly monocytes to mediate antibody-dependent cellular cytotoxicity (ADCC). Overall, our data identifies a new immune-evasion activity used by SARS-CoV-2 to escape humoral responses.

Since the discovery of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in early 2020 in Wuhan, China (1-3), major advances have been made in understanding this virus and the disease it causes. A large part of these advances have focused on one SARS-CoV-2 protein, its Spike, which resulted in the development of Spike therapeutic antibodies that reached the clinic and currently-approved vaccines.

However, SARS-CoV-2 has a large and complex genome coding for 26 proteins (4) which all play essential roles in viral replication and pathogenesis. Most of these viral proteins remain unfortunately poorly studied compared to the Spike glycoprotein. This include the small (121 amino acids) rapidly evolving accessory protein ORF8 (5) . This protein has two dimerization interfaces (6) and has been linked to immune evasion.

Notably, ORF8 was shown to directly interact with major histocompatibility complex class I molecules (MHC-I) and mediate their downregulation by targeting them to lysosomal degradation via autophagy rendering infected cells more resistant to lysis by cytotoxic T cells (7) . Interestingly, a recent study has shown that ORF8 is secreted from infected cells, can be detected in the plasma of acutely-infected individuals, and is negatively associated with survival (8) . Whether this association is linked to its capacity to induce a cytokine storm remains to be determined (9) .

Vaccine-elicited humoral responses were shown to protect from infection and severe disease (10, 11) . Anti-SARS-CoV-2 Spike-specific antibodies can mediate a wide range of actions from viral neutralization to different Fc-mediated effector functions.

Among the later, antibody-dependent cellular cytotoxicity (ADCC) and antibodydependent cellular phagocytosis (ADCP) result in the elimination of infected cells. In the transgenic human ACE2 K18 mice model, Fc-mediated effector functions of neutralizing antibodies have been shown to be required for protection from lethal challenges (12) .

Similarly, strong Fc-mediated effector functions, in the absence of neutralization, were sufficient to significantly delay death (13) . Furthermore, Fc-mediated effector functions were associated with survival in acutely infected individuals (14, 15) . Altogether, these results suggest that Fc-effector functions have a major impact on virus clearance and disease outcomes. Accordingly, Fc-effector functions were associated with protection from infection by emerging SARS-CoV-2 variants of concern (16). These documented inhibitory impacts of Fc-effector functions on virus replication and disease might explain why viruses have developed sophisticated strategies to evade this important immune function (17) (18) (19) (20) . For example, HIV-1 uses two accessory proteins, Nef and Vpu, to protect infected cells from ADCC responses (21) (22) (23) (24) . Other viruses, such as Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), murine cytomegalovirus (MCMV), human cytomegalovirus (HCMV) and varicella-zoster virus (VZV) secrete proteins that bind to the Fc portion of host immunoglobulins (25) (26) (27) (28) . These virally encoded Fc binding proteins are thought to contribute to protection from Fc-effector functions. Since acute SARS-CoV-2 infection is associated with a loss of CD16+ cells, in the present study we evaluated whether soluble ORF8 could modulate Fc-effector functions.

We first evaluated whether ORF8 could interact with different cell types present in peripheral blood mononuclear cells (PBMCs). To investigate this possibility, recombinant ORF8 was conjugated with FITC and incubated on ice with PBMCs for 30 minutes. Ten percent of cells present in PBMCs were bound by ORF8 (Fig. 1A) . By further investigating which cell type bound ORF8 using anti-CD14, anti-CD16 and anti-CD56 antibodies, we found that ORF8 bound monocytes (CD14+CD16+) as well as NK cells (CD56+CD16+) (Fig. 1A) . Because it has been previously shown that ORF8 adopts an Ig-like fold (6) and because CD16 is a common receptor at the surface of these two cell types, we asked whether ORF8 could directly interact with CD16a. Using bio-layer interferometry (BLI), we measured the affinity of recombinant ORF8 with the CD16a ectodomain. As presented in figure 1B , ORF8 bound CD16a with nanomolar affinity (38.9 nM, Fig. 1B ).

CD16 interacts with the Fc portion of IgG and is present at the surface of different cell types including NK cells and monocytes. Upon binding a sufficient amount of antibodies, these cells get activated and can mediate ADCC. To evaluate whether ORF8 could modulate this response, we first assessed whether ORF8 modulated CD16 levels at the surface of NK cells and monocytes. Briefly, PBMCs were incubated overnight with ORF8 as described in material and methods. Sixteen hours after ORF8 treatment, PBMCs were stained with anti-CD3, anti-CD14, anti-CD56 and anti-CD16 antibodies and analyzed by flow cytometry to measure CD16 levels at the surface of NK cells and monocytes. As presented in figure 1C , the surface level of CD16 on monocytes present within the PBMC population was significantly decreased upon treatment with ORF8.

When looking at CD16 at the surface of NK cells, a smaller, but significant, decrease was also observed (Fig. 1D ). To evaluate if ORF8 directly acted on monocytes to decrease their CD16 level, we repeated the experiment using monocytes purified from PBMCs. As shown in supplemental figure 1A, addition of soluble ORF8 to purified monocytes modulated CD16 levels in a manner similar to when added to total PBMCs, therefore suggesting a direct effect of ORF8 on monocytes. To verify if the decreased CD16 levels at the surface of NK cells also depends on the presence of monocytes, ORF8 was added to monocyte-depleted PBMCs. As shown in supplemental figure 1B, the small decrease on NK cells was not observed upon monocyte depletion, confirming the role of monocytes in ORF8-mediated downmodulation of CD16 on NK cells. These results suggest that monocytes represent an important target of ORF8. We next evaluated if the observed decrease of CD16 at the surface of monocytes and NK cells affected ADCC responses with in vitro assay which uses PBMCs as effector cells (29, 30) . We first produced soluble ORF8 in culture media by transfecting HEK293T cells with ORF8 DNA. In agreement with previous data showing ORF8 secretion (8, 9) , we also observed ORF8 secretion and supernatant accumulation ( Fig.   2A ). PBMCs were treated overnight with ORF8-conditioned media before being used as effector cells in the ADCC assay. In agreement with ORF8-mediated CD16 downregulation, soluble ORF8 significantly decreased ADCC responses mediated by plasma from convalescent and vaccinated individuals ( Fig. 2B-D) . The contribution of monocytes in these results was assessed using ORF8-treated monocytes. In agreement with decreased CD16 levels at the surface of ORF8-treated monocytes, we observed a significant decline in monocyte-mediated ADCC (Fig. 2E ). Of note, the decrease in CD16 levels and ADCC responses after the addition of ORF8 to total PBMCs or purified monocytes was similar (Supplemental Figure 1 C and D) , suggesting that the impact of ORF8 on PBMCs is mostly dependent on monocytes.

Vaccine-elicited humoral responses are associated with vaccine efficacy against SARS-CoV-2 infection and protection from severe disease (10, 11) . In response to the antibodies produced by vaccinated and already infected individuals, multiple variants are emerging (31) . A common feature of these variants is the apparition of multiple mutations in the Spike. These mutations decrease antibody recognition which cause immune evasion and increased transmissibility (31) . Mutations were also observed in ORF8 but their effect(s) on immune evasion remain largely unknown. Our results raise the intriguing possibility that emerging variants use ORF8 to evade Fc-effector functions by impairing monocytes and to a lesser extent NK cells to mediate ADCC.

The authors thank the CRCHUM Flow Cytometry Platforms for technical assistance. 

The study was conducted in accordance with the Declaration of Helsinki in terms of The CEM.NKr CCR5+ and CEM.NKr.Spike cells were previously described (29) and maintained in complete media.

Three million HEK293T cells were seeded on 100 mm petri dishes. The following day, the HEK293T cells were transfected with 10 µg of ORF8 DNA using standard calcium phosphate. 16 hours later, the media was changed. 24 hours after the media was changed, the cell supernatant was centrifuged at 484 x g and aliquoted in 1.5 mL tubes.

The tubes were then stored at -80°C until further use. AP184P) for 1 hour at room temperature. The membrane was treated with the ECL (Enhanced chemiluminescence) reagent, proteins signals were exposed to the X-ray films. 

Binding kinetics were performed on an Octet RED96e system (FortéBio) at 25°C with shaking at 1,000 RPM. Amine Reactive Second-Generation (AR2G) biosensors were hydrated in water, then activated for 300 s with an S-NHS/EDC solution (Fortébio) prior to amine coupling. CD16a ectodomain (Human CD16a, amino acids Met1-Gln208 (Accession # P08637-1) with a C-terminal His-tag, ThermoFischer Scientific, catalogue number A42538) was loaded into AR2G biosensor at 12.5 µg/mL in 10mM acetate solution pH 5 (Fortébio) for 600 s and then quenched into 1M ethanolamine solution pH 8.5 (Fortébio) for 300 s. Baseline equilibration was collected for 120 s in 10X kinetics buffer. Association of ORF8 protein (SARS-CoV-2 ORF8 (aa16-121), His Tag (RP-87666), ThermoFischer Scientific) (in 10X kinetics buffer) to CD16a ectodomain was carried out for 180 s at various concentrations in a two-fold dilution series from 500nM to 31.25nM prior to dissociation for 300 s. The data were baseline subtracted prior to fitting performed using a 1:1 binding model in the FortéBio data analysis software. Calculation of on-rates (Ka), off-rates (Kdis), and affinity constants (KD) was computed using a global fit applied to all data.

PBMCs, purified monocytes or PBMCs depleted in monocytes from different donors were treated with mammalian produced ORF8 for 16 hours at 37°C and 5% CO2. 

This assay was previously described (29, 30) Supplemental Figure 1 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A new coronavirus associated with human respiratory disease in China

China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China

The coding capacity of SARS-CoV-2

On the origin and continuing evolution of SARS-CoV-2

Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein

The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Iota

Secreted ORF8 is a pathogenic cause of severe Covid-19 and potentially targetable with select NLRP3 inhibitors

ORF8 contributes to cytokine storm during SARS-CoV-2 infection by activating IL-17 pathway

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Evidence for antibody as a protective correlate for COVID-19 vaccines

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

A Fcenhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections

Human cytomegalovirus Fcgamma binding proteins gp34 and gp68 antagonize Fcgamma receptors I, II and III

Elevated plasma-soluble CD16 levels in porcine reproductive and respiratory syndrome virus-infected pigs: correlation with ADAM17-mediated shedding

Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity

Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. Vaccines (Basel)

Role of HIV-1 Envelope Glycoproteins Conformation and Accessory Proteins on ADCC Responses

Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity

The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals

Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses

Characteristics of the Fc receptor induced by herpes simplex virus

Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin

Cell surface expression of the varicellazoster virus glycoproteins and Fc receptor

Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor

A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

The great escape? SARS-CoV-2 variants evading neutralizing responses